stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Debt to equity
Denali Therapeutics Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, up 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2023) to 0.2× (fiscal 2019); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | 19.57% |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.1× | (17.13%) |
| FY2021 | 0.1× | 10.25% |
| FY2020 | 0.1× | (68.17%) |
| FY2019 | 0.2× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | (10.61%) |
| Jun 2026 | 0.0× | 11.86% |
| Mar 2026 | 0.0× | 7.27% |
| Dec 2025 | 0.0× | (8.33%) |
| 37 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| CELC Celcuity, Inc. compare | −58.9× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 0.0× |
| ELVN Enliven Therapeutics, Inc. compare | 0.0× |
| DNLI Denali Therapeutics Inc. | 0.0× |
| DYN Dyne Therapeutics, Inc. compare | 0.3× |
| VKTX Viking Therapeutics, Inc. compare | 0.4× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 0.7× |
| TLX Telix Pharmaceuticals Limited compare | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement